News
Here's Why Invitae Rose as Much as 13.8% Today
Shares of genomics leader Invitae (NYSE: NVTA) rose nearly 14% Tuesday after the company reported third-quarter 2017 earnings Monday afternoon. Investors have become accustomed to eye-popping....
Is This Why Glaukos Corp. Is Tumbling Today?
Shares of Glaukos (NYSE: GKOS), a medical-device company focused on glaucoma, fell 12% as of 3:25 p.m. EST on Tuesday on heavy volume. However, there wasn't any news that can help to explain the
Here's Why Spark Therapeutics, Inc. Fell 9.3% in October
Shares of Spark Therapeutics, Inc. (NASDAQ: ONCE), a clinical-stage biotech advancing a once-and-done gene therapy approach to treating genetic disorders, have given back some of August's gains.....
The Single Event That Rocketed Arena Pharmaceuticals, Inc. Higher by 10% in October
Shares of Arena Pharmaceuticals (NASDAQ: ARNA), a small-cap biotech company with a focus on a broad array of specialty disease indications, vaulted higher by 10% during the month of October,....
Why Valeant Pharmaceuticals International Stock Is Shooting Higher Today
Valeant Pharmaceuticals International (NYSE: VRX) stock is up by double-digits today on heavy volume as the result of a better-than-expected third-quarter earnings release. Although the company....
Valeant Pharmaceuticals Posts a Huge Third-Quarter Profit -- but There's a Catch
Valeant Pharmaceuticals (NYSE: VRX) CEO Joe Papa has referred to the company in the past as "the turnaround opportunity of a lifetime." A key part of his turnaround strategy has been reducing the....
Exelixis, Inc. Looks Ahead -- but the 3rd Quarter Wasn't Too Shabby
Exelixis (NASDAQ: EXEL), the biotech once left for dead by quite a few investors, continues its resurgence with another solid quarter of sales of its kidney cancer drug Cabometyx. Of course, the....
What's Behind GW Pharmaceuticals' 6.4% Gain in October?
Shares of GW Pharmaceuticals plc (NASDAQ: GWPH), a company developing an epilepsy drug derived from its cannabinoid product platform, tacked on another 6.4% in October according to data from....
GW Pharmaceuticals Just Delivered Some Good News About Its Marijuana-Based Drug
This year has been a real seesaw for shareholders of GW Pharmaceuticals (NASDAQ: GWPH). Lately, that seesaw is tipping up slightly, following news that a cannabidiol-based drug candidate the....
2 Figures That'll Tell Us if Valeant Pharmaceuticals' Business Is Improving
In recent years, a Valeant Pharmaceuticals (NYSE: VRX) quarterly earnings report was grounds to call out sick from work, bury yourself under the blankets, and pray you'd still have money left when....
3 Stocks to Buy for a Better Tomorrow
Buy low, and sell high. In investing, as in life, we all hope for "a better tomorrow," and one in which the decisions we make today ultimately pay off -- figuratively, and, in the case of stocks,....
True or False: Republicans Support Legalizing Marijuana?
Chances are that you'd struggle to find an industry within the U.S. that's growing at a faster and more consistent pace than legal marijuana.Colorado, one of the eight states that's legalized....
3 Biotech Stocks That Soared This Week: Are They Buys?
Halloween week produced treats instead of tricks for some biotech investors. Quite a few biotech stocks rose by double-digit percentages, with three in particular soaring close to 30% and higher....
Why Emergent BioSolutions Inc. Jumped Higher Today
Emergent BioSolutions (NYSE: EBS) is up 11.4% at 1:00 p.m. EDT after announcing third-quarter earnings following the closing bell yesterday. It was a solid quarter for the biodefense specialist,....
Here's Why Insulet Corporation's Investors Are Pumped
In response to the company's upbeat third-quarter results and raised guidance, shares of Insulet Corporation (NASDAQ: PODD), a medical device maker focused on diabetes and drug delivery, rose 16%....
Insulet Posts 28% Revenue Growth and Raises 2017 Outlook on Soaring International Sales
Insulet (NASDAQ: PODD) reported solid third-quarter 2017 financial results after the market closed on Thursday. The drug delivery company, which is a leader in tubeless insulin pump technology....
3 Reasons Behind Exelixis Stock's Big Bounce
After experiencing a dismal September and sliding quite a bit over the last few weeks after a rebound, Exelixis (NASDAQ: EXEL) stock enjoyed a big bounce on Thursday. The biotech announced its....
The Precision Medicine Stock That's Revolutionizing Cancer Treatment
Foundation Medicine's (NASDAQ: FMI) genetic screening tests are leading the way in discovering what medicines will work best in cancer patients based on their DNA. As more specialized drugs....
Here's Why bluebird bio Inc. Is Surging Again Today
Shares of bluebird bio Inc. (NASDAQ: BLUE), a clinical-stage biotech developing cell-based therapies, are on the move for the second day in a row. Yesterday, the stock jumped in response to a....
The Clear Reason Exelixis, Inc. Rocketed Higher by as Much as 10%
Shares of Exelixis (NASDAQ: EXEL), a mid-cap drug developer with a focus on novel cancer therapies, rocketed higher by as much as 10% during Thursday's trading session after the company reported....
Why Juno Therapeutics Shares Are Going Up 21.2% Today
After the company released its third-quarter progress report and shared the latest data from its lead drug, JCAR017, shares of Juno Therapeutics (NASDAQ: JUNO) are shooting 21.2% higher at 2:30....
Here's Why Alnylam's Gain Is Ionis Pharmaceuticals' Loss Today
As of 1:18 p.m. EDT on Thursday, shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) are up 13.7%, while shares of its biotech peer Ionis Pharmaceuticals Inc. (NASDAQ: IONS) are down....
Here's Why Myriad Genetics Dropped as Much as 18.6%
Shares of genetic-testing leader Myriad Genetics (NASDAQ: MYGN) dropped over 18% today. That may have investors confused, especially considering the company today announced that its GeneSight....
Here's Why Neurocrine Biosciences Is Soaring
In response to the company reporting better-than-expected quarterly results, shares of Neurocrine Biosciences (NASDAQ: NBIX), a commercial stage biotech focused on neurological and endocrine....
Juno Therapeutics' 3rd Quarter Boosted by Potential Rival Novartis
It's a great time to be a biotech focused on CAR-T (chimeric antigen receptor T-cell therapy). Juno Therapeutics (NASDAQ: JUNO) stock has soared so far in 2017, partially due to its own good....